
Privacy notice | Accessibility statement | Terms and conditions | Login | Contact |
UK data driving real-world evidence
Bibliography
Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,700 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 6 April 2021) and papers are listed below and in the PDF below.
If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.
Download:
(PDF, 5MB, 226 pages)This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website.
“Commonly used medications and endometrial cancer survival: a population-based cohort study”, Br J Cancer, vol. 117, pp. 432-438, 2017.
, “Digoxin use after diagnosis of prostate cancer and survival: a population-based cohort study”, Pharmacoepidemiol Drug Saf, vol. 25, pp. 1099-103, 2016.
, “Metformin use and survival after colorectal cancer: A population-based cohort study”, Int J Cancer, vol. 138, pp. 369-79, 2016.
, “The association between glucose-lowering drug use and mortality among breast cancer patients with type 2 diabetes”, Breast Cancer Res Treat, vol. 150, pp. 427-37, 2015.
, “Clopidogrel use and cancer-specific mortality: a population-based cohort study of colorectal, breast and prostate cancer patients”, Pharmacoepidemiol Drug Saf, vol. 24, pp. 830-40, 2015.
, “Digoxin use after diagnosis of breast cancer and survival: a population-based cohort study”, Breast Cancer Res Treat, vol. 151, pp. 661-9, 2015.
, “Digoxin use after diagnosis of colorectal cancer and survival: a population-based cohort study”, Cancer Epidemiol Biomarkers Prev, vol. 24, pp. 1804-7, 2015.
, “The effect of warfarin therapy on breast, colorectal, lung, and prostate cancer survival: a population-based cohort study using the Clinical Practice Research Datalink”, Cancer Causes Control, vol. 26, pp. 355-66, 2015.
, “Post-diagnostic oral bisphosphonate use and colorectal cancer mortality: a population-based cohort study within the UK Clinical Practice Research Datalink”, Br J Cancer, vol. 113, pp. 123-6, 2015.
, “Statin use after diagnosis of breast cancer and survival: a population-based cohort study”, Epidemiology, vol. 26, pp. 68-78, 2015.
, “Statin use and survival from lung cancer: a population-based cohort study”, Cancer Epidemiol Biomarkers Prev, vol. 24, pp. 833-41, 2015.
, “Beta-blocker usage after malignant melanoma diagnosis and survival: a population-based nested case-control study”, Br J Dermatol, vol. 170, pp. 930-8, 2014.
, “Drugs affecting the renin-angiotensin system and survival from cancer: a population based study of breast, colorectal and prostate cancer patient cohorts”, BMC Med, vol. 12, p. 28, 2014.
, “Low-dose aspirin and survival in men with prostate cancer: a study using the UK Clinical Practice Research Datalink”, Cancer Causes Control, vol. 25, pp. 33-43, 2014.
, “Low-dose aspirin use after diagnosis of colorectal cancer does not increase survival: a case-control analysis of a population-based cohort”, Gastroenterology, vol. 146, pp. 700-708.e2, 2014.
, “Post-diagnostic prescriptions for low-dose aspirin and breast cancer-specific survival: a nested case-control study in a breast cancer cohort from the UK Clinical Practice Research Datalink”, Breast Cancer Res, vol. 16, p. R34, 2014.
, “Statin use after colorectal cancer diagnosis and survival: a population-based cohort study”, J Clin Oncol, vol. 32, pp. 3177-83, 2014.
, “Beta-blocker usage and breast cancer survival: a nested case-control study within a UK clinical practice research datalink cohort”, Int J Epidemiol, vol. 42, pp. 1852-61, 2013.
, “beta-Blocker usage and colorectal cancer mortality: a nested case-control study in the UK Clinical Practice Research Datalink cohort”, Ann Oncol, vol. 24, pp. 3100-6, 2013.
, “Non-steroidal anti-inflammatory drug use and brain tumour risk: a case-control study within the Clinical Practice Research Datalink”, Cancer Causes Control, vol. 24, pp. 2027-34, 2013.
, “Non-steroidal anti-inflammatory drug use and cervical cancer risk: a case-control study using the Clinical Practice Research Datalink”, Cancer Epidemiol, vol. 37, pp. 897-904, 2013.
, “Exposure to oral bisphosphonates and risk of cancer”, Int J Cancer, vol. 131, pp. E717-25, 2012.
, “Proton pump inhibitors and histamine-2-receptor antagonists and pancreatic cancer risk: a nested case-control study”, Br J Cancer, vol. 106, pp. 233-9, 2012.
, “Exposure to oral bisphosphonates and risk of esophageal cancer”, Jama, vol. 304, pp. 657-63, 2010.
, “Non-steroidal anti-inflammatory drugs and pancreatic cancer risk: a nested case-control study”, Br J Cancer, vol. 102, pp. 1415-21, 2010.
, “Statins and pancreatic cancer risk: a nested case-control study”, Cancer Causes Control, vol. 21, pp. 2093-100, 2010.
, “Infections in early life and childhood leukaemia risk: a UK case-control study of general practitioner records”, Br J Cancer, vol. 99, pp. 1529-33, 2008.
,